Amgen is the latest drugmaker to have a Herceptin biosim sidelined by a CRL

herceptin
Another biosimilar of Roche's $7 billion chemo drug Herceptin has been hit with a CRL, this one from Allergan and Amgen. (Roche)

Amgen, in a two-sentence announcement today, said it received a complete response letter for the biosimilar of Roche’s cancer med Herceptin it developed with Allergan. It marks the third Herceptin biosimilar that has been stalled by the FDA but has won approval in Europe.

The Thousand Oaks, California-based drugmaker offered no insight into what the FDA found lacking in its version. “We will work closely with the FDA to bring this important medicine to patients in the U.S. We do not expect this to impact our U.S launch plan,” it said in the announcement.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Biosimilar makers have been hot to develop their own versions of Roche’s Herceptin, a long-in-the tooth oncology drug that still raked in $2.5 billion in U.S. sales last year and $7 billion worldwide. Mylan and partner Biocon, Pfizer and now Amgen have all had their initial applications delayed by U.S. regulators. Pfizer just today won an European Medicines Agency approval for its Trazimera.

None of the drugmakers have provided much detail as to what triggered their CRLs, so it is unknown whether there has been a common theme for the denials or what the hangup is for the FDA that has not bothered the EMA. FDA concerns about Biocon’s Indian plant figured into the FDA's delay of the version from Mylan and its Indian partner.  

RELATED: Mylan and Biocon win FDA nod for Herceptin copy and move biosim forward in EU

Mylan and Biocon won an FDA thumbs-up for their Herceptin biosimilar in December, but only after a three-month delay in which the FDA looked over some new technical data that had resulted from changes made in their manufacturing operations. When the partners got consideration of their version delayed, it looked like they would go from the front of the line to the back of the line as the FDA considered applications from other drugmakers. But the partners ended up being the first to win approval as competitors also had their versions sidelined.

These delays have allowed Roche to continue to go to the Herceptin cash machine. Despite recent approvals for biosimilars in the EU, Herceptin sales worldwide were up 3% last year to about $7 billion on higher sales in the U.S. and Brazil. While most of those sales come from the U.S., $2.7 billion, EU revenue is also significant, at $2.1 billion.

RELATED: FDA to Pfizer: To win OK for Herceptin biosimilar, fork over more 'technical' info

While regulatory and manufacturing stumbles have protected Roche’s Herceptin sales, the Swiss drugmaker is also throwing up roadblocks. Last fall, Roche sued Pfizer for infringement on 40 Herceptin patents, asking a court to block a potential biosim launch. Pfizer said it will defend its "position vigorously and in the appropriate venue."